Phase I study of lower dose CPX-351 combined with venetoclax for patients with higher-risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure
Phase I trial shows combined CPX-351 and venetoclax achieves 84% overall response in patients with high-risk MDS or chronic myelomonocytic leukemia, suggesting an effective approach.
Key Points
Eighty-four percent of patients achieved an overall response rate after treatment with CPX-351 and venetoclax.
Most common grade ≥3 treatment-emergent adverse events were thrombocytopenia and febrile neutropenia affecting 50% and 33% respectively.
This phase I clinical trial utilized a Bayesian optimal interval design to determine maximum tolerated dose of the combination therapy.
Results highlight the need for continued evaluation in larger cohorts to confirm efficacy and safety of the CPX-351 and venetoclax combination.